RecruitingInterventionalPhase 2Last updated Nov 3, 2025

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage 2 B-IV Hodgkin Lymphoma

Overview

ClinicalTrials.gov ID: NCT07002216
Lead Sponsor: University of MiamiOTHER
Brief Summary: The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.

Status

Overall Status: Recruiting
Start Date: Jul 15, 2025Actual
Primary Completion Date: Jul 15, 2030Estimated
Completion Date: Jul 15, 2030Estimated

Study Record Dates

First Submitted: May 23, 2025
First Submitted that Met QC Criteria: May 23, 2025
First Posted: Jun 3, 2025Actual
Last Update Submitted that Met QC Criteria: Oct 30, 2025
Last Update Posted: Nov 3, 2025Actual
Last Verified: Oct 2025

NCT06919679Not yet recruiting

Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

NCT02661503Unknown status

HD21 for Advanced Stages

NCT05922904Active, not recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

NCT03527628Unknown status

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

NCT02166463Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT04334174Withdrawn

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas